Ann: New clinical data for DEP cabazitaxel in prostate cancer, page-23

Yes @WBA there is a lot of ASX biotech activity today .... another ASX listed biotech had a Director buy shares on market in excess of $120,000 debunking any theories on here that JF & Co. can't buy shares due to a blackout period at these 5 year low share prices and let me explain why....


..... this particular biotech has openly declared in recent financial reporting and a subsequent investor conference call last month that they are in the middle of multiple partnership negotiations at present; are resubmitting their BLA by 30 Sept for one indication; they are also waiting an FDA decision on possible AA pathway for another one of its indications; etc etc .... so tell me again why JF & Co. cannot buy shares on market in Starpharma ? I am all ears because surely all ASX biotechs are subject to the same ASX compliance rules and other ASX biotech seem to have a lot more material information pending than Starpharma yet Directors are buying on market


Starpharma has now issued its June Quarterly and its Annual Report and today these long awaited DEP® cabazitaxel limited trial results so all that is left is the 'licensing negotiations' or a TGA approval (if that ever eventuates) .... we know some 'well advanced negotiations' 15 months on from ASX reporting of same by Starpharma are still not finalised so again I am all ears as to why JF & Co. cannot buy on market at these depressed prices ?